New Formulation
- Remsima SC
-
Celltrion developed Remsima SC (hypodermic injection type), which offers more a convenient injection compared to Remsima IV (intravenous injection type).
Remsima SC can be administered by patients themselves and is expected to be a game-changer for the global blockbuster pharmaceutical market. Celltrion recently received EMA approval for RemsimaSC.
- Efficacy and safety
-
Celltrion has proven the efficacy and safety of Remsima SC through large-scale clinical trials.
Remsima SC demonstrated slightly better efficacy than Remsima IV in the ACR and EULAR tests. The trial also found that it is not inferior to Remsima IV in terms of efficacy and safety.ACR Response after Injection with Remsima SC and Remsima IV
- More Convenient
Injection -
Remsima SC is the first hypodermic injection-type Infliximab with enhanced convenience for patients. One of the significant issues with the original Infliximab is that it is difficult to inject. On the other hand, Remsima SC can be easily injected by patients, which significantly reduces their visits to the hospital as well as the time required for injection.
-
Fewer visits
to the hospital -
Can be
self-injected -
Reduced injection
time
- Wider treatment options
-
Celltrion’s Dual Formation option prescribes Remsima IV to patients requiring fast action without immunogenicity and safety risks caused by cross-prescription and prescribes Remsima SC to patients with improved conditions. This strategy maximizes the effectiveness of treatment while maintaining their efficacy.
Remsima SC is expected to present a new treatment option for patients who want more convenient SC formulation and those who did not benefit from existing drugs,* as well as medical practitioners who want to administer Infliximab IV for faster action and then change the formulations Later.Dual Formulation Option
-
Intravenous injection
for faster action -
Maintain hypodermic
injection
Change of Remsima IV and Remsima SC Concentrations in Blood After Administration
-
